Medical Genetics seminars
April 2024
Modeling human brain development and disease: the role of primary cilia
Kyrousi Christina· Medical School, National and Kapodistrian University of Athens, Athens, Greece
Wed, Apr 24 · 14:00 UTC · Online
Neurodevelopmental disorders (NDDs) impose a global burden, affecting an increasing number of individuals. While some causative genes have been identified, understanding the human-specific mechanisms involved in these disorders remains limited. Traditional gene-driven approaches for modeling brain diseases have failed to capture the diverse and convergent mechanisms at play. Centrosomes and cilia act as intermediaries between environmental and intrinsic signals, regulating cellular behavior. Mutations or dosage variations disrupting their function have been linked to brain formation deficits, highlighting their importance, yet their precise contributions remain largely unknown. Hence, we aim to investigate whether the centrosome/cilia axis is crucial for brain development and serves as a hub for human-specific mechanisms disrupted in NDDs. Towards this direction, we first demonstrated species-specific and cell-type-specific differences in the cilia-genes expression during mouse and human corticogenesis. Then, to dissect their role, we provoked their ectopic overexpression or silencing in the developing mouse cortex or in human brain organoids. Our findings suggest that cilia genes manipulation alters both the numbers and the position of NPCs and neurons in the developing cortex. Interestingly, primary cilium morphology is disrupted, as we find changes in their length, orientation and number that lead to disruption of the apical belt and altered delamination profiles during development. Our results give insight into the role of primary cilia in human cortical development and address fundamental questions regarding the diversity and convergence of gene function in development and disease manifestation. It has the potential to uncover novel pharmacological targets, facilitate personalized medicine, and improve the lives of individuals affected by NDDs through targeted cilia-based therapies.
January 2024
Genomic investigation of sex-differential neurodevelopment and risk for autism
Donna Werling· University of Wisconsin-Madison
Wed, Jan 31 · 05:00 UTC · Online
November 2023
X-linked mosaicism and behavioral heterogeneity in Rett syndrome
Keerthi Krishnan· University of Tennessee, Knoxville
Wed, Nov 1 · 06:00 UTC · Online
June 2023
Epilepsy genetics 2023: From research to advanced clinical genetic test interpretation
Dennis Lal· Cleveland Clinic
Recorded
The presentation will provide an overview of the expanding role of genetic factors in epilepsy. It will delve into the fundamentals of this field and elucidate how digital tools and resources can aid in the re-evaluation of genetic test results. In the initial segment of the presentation, Dr. Lal will examine the advancements made over the past two decades regarding the genetic architecture of various epilepsy types. Additionally, he will present research studies in which he has actively participated, offering concrete examples. Subsequently, during the second part of the talk, Dr. Lal will share the ongoing research projects that focus on epilepsy genetics, bioinformatics, and health record data science.
May 2023
Precision Genomics in Neurodevelopmental Disorders
Tychele Turner· Washington University
Wed, May 3 · 05:00 UTC · Online
February 2023
Focal Cortical Dysplasia (FCD) is the most common focal cortical malformation leading to intractable childhood focal epilepsy. In recent years, we and others have shown that FCD type II is caused by mosaic mutations in genes within the PI3K-AKT-mTOR-signaling pathway. Hyperactivation of the mTOR pathway accounts for neuropathological abnormalities and seizure occurrence in FCD. We further showed from human surgical FCDII tissue that epileptiform activity correlates with the density of mutated dysmorphic neurons, supporting their pro-epileptogenic role. The level of mosaicism, as defined by variant allele frequency (VAF) is thought to correlate with the size and regional brain distribution of the lesion such that when a somatic mutation occurs early during the cortical development, the dysplastic area is smaller than if it occurs later. Novel approaches based on the detection of cell-free DNA from the CSF and from trace tissue adherent to SEEG electrodes promise future opportunities for genetic testing during the presurgical evaluation of refractory epilepsy patients or in those that are not eligible for surgery. In utero-based electroporation mouse models allow to express somatic mutation during neurodevelopment and recapitulate most neuropathological and clinical features of FCDII, establishing relevant preclinical mouse models for developing precision medicine strategies.
December 2022
The impact of emerging technologies and methods on the interpretation of genetic variation in autism and fetal genomics
Michael Talkowski· Massachusetts General Hospital, Broad Institute of MIT and Harvard, Harvard Medical School
Wed, Dec 7 · 05:00 UTC · Online
July 2022
Role of ASD risk genes on maturation of frontal-sensory cognitive control circuit
Hiro Morishita· Icahn School of Medicine at Mount Sinai
Wed, Jul 27 · 05:00 UTC · Online
November 2021
Stem cell approaches to understand acquired and genetic epilepsies
Jenny Hsieh· University of Texas at San Antonio
Wed, Nov 17 · 16:00 UTC · Online
The Hsieh lab focuses on the mechanisms that promote neural stem cell self-renewal and differentiation in embryonic and adult brain. Using mouse models, video-EEG monitoring, viral techniques, and imaging/electrophysiological approaches, we elucidated many of the key transcriptional/epigenetic regulators of adult neurogenesis and showed aberrant new neuron integration in adult rodent hippocampus contribute to circuit disruption and seizure development. Building on this work, I will present our recent studies describing how GABA-mediated Ca2+ activity regulates the production of aberrant adult-born granule cells. In a new direction of my laboratory, we are using human induced pluripotent stem cells and brain organoid models as approaches to understand brain development and disease. Mutations in one gene, Aristaless-related homeobox (ARX), are of considerable interest since they are known to cause a common spectrum of neurodevelopmental disorders including epilepsy, autism, and intellectual disability. We have generated cortical and subpallial organoids from patients with poly-alanine expansion mutations in ARX. To understand the nature of ARX mutations in the organoid system, we are currently performing cellular, molecular, and physiological analyses. I will present these data to gain a comprehensive picture of the effect of ARX mutations in brain development. Since we do not understand how human brain development is affected by ARX mutations that contribute to epilepsy, we believe these studies will allow us to understand the mechanism of pathogenesis of ARX mutations, which has the potential to impact the diagnosis and care of patients.
October 2021
Tackling the vulnerable brain in rare genetic neurodevelopmental syndromes
Tjitske Kleefstra· Radboudumc
Wed, Oct 13 · 05:00 UTC · Online
March 2021
February 2021
Proyecto: Registro español SYNGAP1 - historia natural y estudio del sueño, Share4Rareplatform
Juliana Ribeiro Constant, MD· Proyecto SYNGAP1 (España)
Fri, Feb 19 · 04:30 UTC · Online
Características generales de la encefalopatía epiléptica y desarrollo en SYNGAP1
Andrés Jiménez Gómez, MD· Joe DiMaggio Children's Hospital (Estados Unidos) -
Fri, Feb 19 · 02:00 UTC · Online
January 2021
Cognition, behaviour and clinical trials in SYNGAP1
Andrew Stanfield· The University of Edinburgh
Thu, Jan 14 · 15:30 UTC · Online
October 2020
De novo mutations in autism and contributions from sperm mosaicism
Joseph Gleeson· UC San Diego; Rady Children's Institute for Genomic Medicine
Wed, Oct 7 · 05:00 UTC · Online
End of results.